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Objectives: Intravesical injection of onabotulinumtoxinA (BoNT-A) provides effective treatment for
idiopathic detrusor overactivity (IDO). However, not all patients have successful long-term therapeutic
effects. This study investigated the effects of baseline urodynamic parameters on the therapeutic
outcome, after injecting 100 U BoNT-A in patients with IDO.
Materials and Methods: A total of 174 patients who received a ﬁrst single intravesical BoNT-A 100 U
injection for refractory IDO were included. A successful outcome was deﬁned as an improvement of at
least two points on a patient perception of bladder condition scale, which was scored from 0 to 6. The
short-term (3 months) and long-term (up to 24 months) success rates were analyzed according to
baseline urodynamic parameters, including cystometric bladder capacity, maximum ﬂow rate, postvoid
residual, voiding efﬁciency, and detrusor overactivity (DO) subtypes. BoNT-A- related adverse events
were also reported.
Results: A successful outcome was reported by 138 (79.3%) patients at 3 months. The baseline urody-
namic parameters did not affect the success rates, except that patients with phasic DO had a signiﬁcantly
higher success rate at 3 months than patients with terminal DO. Patients with a baseline postvoid
residual (PVR) > 100 mL, had higher rates of acute urinary retention and need to strain to void. However,
long-term success rates up to 24 months showed no signiﬁcant differences between patients with
different urodynamic parameters.
Conclusions: Except for patients with phasic DO, the baseline urodynamic parameters did not affect the
treatment outcome of intravesical injection of 100 U BoNT-A for IDO. However, acute urinary retention
and difﬁcult urination occurred more often in patients with a baseline PVR of > 100 mL.
Copyright  2012, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Intravesical injection of onabotulinumtoxinA (BoNT-A) has
recently been accepted as an alternative treatment for patients with
overactive bladder (OAB) and detrusor overactivity (DO), refractory
to antimuscarinic therapy [1,2]. BoNT-A injection provides an
alternative for non-surgical augmentation of the dysfunctional
bladder. About 50e80% of OAB patients, with or without DO, regain
urinary continence or have improved urinary control [3e5]. Studieshist Tzu Chi General Hospital,
Tel.: þ886 3 8561825x2117;
ddhist Compassion Relief Tzu Chiin which the dose of BoNT-A was decreased from 300 U to 100 U
in the treatment of OAB, found similar therapeutic effects [5e8].
Recent studies revealed a dose of 100 U BoNT-A had acceptable
therapeutic effects and adverse events (AE) [8,9].
The response duration of BoNT-A injection in patients with DO
is closely related to the dose. In one study, detrusor injection of
200 U BoNT-A yielded a response duration of 12e15 months [10],
whereas the therapeutic duration of 100 U BoNT-A was 6e9
months in other studies [11,12]. However, the incidence of AEs is
also closely related to the dose of BoNT-A. Doses > 150 U BoNT-A
contributed minimal additional or clinically relevant improve-
ments in symptoms, but carried higher rates of AE compared with
100 U. Dose dependent changes in the postvoid residual (PVR)
were observed and the use of clean intermittent catheterization
(CIC) was also dose- dependent [9].Foundation. Published by Elsevier Taiwan LLC. All rights reserved.
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istics. Because parasympathetic activity is silent during the storage
phase, a basal release of acetylcholine from non-neuronal (uro-
thelial) as well as neuronal sources has been demonstrated in iso-
lated human detrusor muscle. It is suggested that this release,
which is increased by stretching the muscle and in the aging
bladder, contributes to DO and OAB by eventually increasing
bladder afferent activity during storage [13]. Detrusor contractions
which occur during that phase might be due to increased puri-
nergic activity, or sensor afferent input. Decreased levels of sensory
receptors, including purinergic receptors P2X3 and/or transient
receptor potential vanilloid receptors subfamily 1 (TRPV1), may
contribute to the clinical effect of BoNT-A in DO [14]. Patients with
DO might have adequate or inadequate detrusor contractility [15].
The PVR and voiding efﬁciency (VE) might have signiﬁcant changes
after intravesical BoNT-A injection, causing a large PVR, difﬁcult
urination, acute urinary retention (AUR) or urinary tract infection
(UTI) [16]. In other words, the baseline urodynamic characteristics
might affect the treatment outcome and the occurrence of AEs. The
long-term therapeutic effect might also be affected by baseline
urodynamic parameters.
This study analyzed the therapeutic outcome and AEs after
intravesical injection of 100 U BoNT-A in patients with idiopathic
DO (IDO). The inﬂuence of baseline urodynamic parameters on
therapeutic outcome was also investigated. The results may
provide evidence for us to choose candidates for intravesical
BoNT-A injection and enable urologists to handle the patients
when intravesical BoNT-A injection is planned in the treatment of
patients with IDO.
2. Materials and methods
A total of 174 patients, who had received clinical trials of
intravesical BoNT-A 100 U injection for refractory DO and urinary
incontinence, were included in this study from 2005 to 2010
[4,8,11,17]. The inclusion criteria were: urodynamic DO with or
without urinary incontinence refractory to previous anti-
muscarinics for more than 3 months and no UTI, stress urinary
incontinence, bladder outlet obstruction (BOO) or neurogenic
bladder at enrollment.
Before patients were screened for intravesical BoNT-A injection,
videourodynamic study was routinely used for the diagnosis of
DO and to identify the presence of BOO or intrinsic sphincter
deﬁciency. Patients with a baseline PVR > 150 mL were excluded
from the clinical trials. The cystometric bladder capacity (CBC),
voiding detrusor pressure (Pdet), maximum ﬂow rate (Qmax), and
PVR were recorded. DO was classiﬁed as phasic or terminal DO,
depending on whether the uninhibited detrusor contractions
occurred during the ﬁlling phase, or on reaching bladder capacity,
respectively [18]. All terminology used in this study were in
accordance with the recommendations of the International Conti-
nence Society. Videourodynamic study was performed at baseline
and every 3 months after intravesical BoNT-A injection.
All patients received 100 U BoNT-A using different methods of
intravesical injection, including detrusor or suburothelial injections
in the bladder body, bladder base and trigone injections [8,11,17].
All studies were approved by the Institutional Review Board and
Ethics committee of Tzu Chi General Hospital. All patients were
informed about the advantages and possible AEs and written
informed consent was obtained from all patients before BoNT-A
injection.
One hundred units of BoNT-A (BOTOX, Allergan Inc., Irvine, CA,
USA) were reconstituted to 10e20 mL with normal saline for
detrusor and suburothelial injections, and to 10 mL with normal
saline for bladder base and trigone injections. Detrusor injectionswere performed by injecting BoNT-A solution into 20e40 sites
about 1 mm in depth, in the lateral wall, posterior wall and dome of
the bladder, using a 23 gauge needle in a rigid cystoscopic injection
instrument (22 Fr, Richard-Wolf, Knittlingen, Germany). The
injection sites were equally distributed in the bladder body. Sub-
urothelial injections were performed using a procedure identical to
that for detrusor injection, except that the needle was inserted just
into the suburothelial space and a ballooning formation was noted
during injection. Bladder base injections were performed by
injecting BoNT-A solution into 10 sites in the suburothelial space
with two injections in a row near the bladder neck and three
injections in a second row anterior, and ﬁve injections posterior, to
the interureteric ridge, about 1 cm from the ureteral oriﬁces.
All procedures were performed transurethrally under intrave-
nous general anesthesia in the operating room. Anticoagulants
were discontinued 1 week before BoNT-A treatment. The bladder
volume was kept at 100e150 mL, and blood vessels were avoided
during injections. An indwelling 14 Fr Foley catheter was placed
overnight and patients were discharged the next morning. Oral
broad spectrum prophylactic antibiotics (cephalosporin 500 mg
tid) were given for 3 days.
Patients were requested to make regular follow-up visits until
their voiding condition returned to baseline. Uroﬂowmetry for
Qmax, voided volume and PVR were performed at each visit. The
functional bladder capacity (FBC) was obtained from the maximum
voided volume recorded in a voiding diary or uroﬂowmetry. The VE
was calculated as the percentage of voided volume of the bladder
capacity measured during urodynamic study or uroﬂowmetry.
All patients were closely monitored at 1e2 weeks, 1 month, 3
months and every 3 months thereafter, until the response to
BoNT-A had disappeared. Patients who failed treatment, were not
followed up after 6 months. The occurrence of urgency episodes
and urgency incontinence were veriﬁed using a 3-day voiding
diary. All patients were requested to grade the treatment outcome
at 3 months after BoNT-A injection (primary end-point), based on
the patient perception of bladder condition (PPBC, scored from 0 to
6), the therapeutic effects and bothersome AE [19]. An improve-
ment in the PPBC score of 2was considered a successful outcome;
otherwise, the treatment was considered to have failed. The period
between the treatment date and the visit that patients reported
disappearance of the therapeutic effect, was deﬁned as the thera-
peutic duration.
Any AE considered possibly related to the BoNT-A treatment was
recorded. These AEs included AUR, hematuria and general weak-
ness in the early post-treatment period, and large PVR, straining to
void, and UTI during the follow-up period. The success rate at 3
months and the urodynamic changes were analyzed between
patients with different baseline urodynamic parameters. Kaplan-
Meier survival curves were used to analyze the cumulative
success rates over time, between subgroups with different baseline
urodynamic parameters. A p value < 0.05 was considered statisti-
cally signiﬁcant.
3. Results
A total of 174 patients were studied, including 85 women and 89
men, aged 18e94 years old, with a median age of 67 years. Forty-
one of the 79 men  50 years old had previously undergone tran-
surethral resection of the prostate. Bladder body injections were
given to 129 patients, and bladder base/trigonal injections were
used in 45 patients. There was no signiﬁcant difference in the mean
age of each baseline variable subgroup.
At 3 months, a successful result was reported by 138 (79.3%)
patients. The success rate at 3 months was not signiﬁcantly different
between any of the baseline urodynamic variable subgroups.
Table 1
The changes of urodynamic variables at baseline and 3 months after intravesical
BoNT-A 100 U injection in patients with detrusor overactivity and different baseline
cystometric bladder capacity.
UDS variables n Baseline 3 mo Changes p#
Qmax
CBC < 250 mL 85 11.0 6.04 11.3 5.78 0.33 4.74 0.136
CBC  250 mL 89 14.0 13.1 13.1 6.71 0.89 5.23
FBC
CBC < 250 mL 85 137 45.6 174.1 84.2 37.2 78.1* 0.000
CBC  250 mL 89 291 106.6 245.8 118.5 45.4 108.1*
PVR
CBC < 250 mL 85 22.4 35.0 88.4 78.8 66.1 76.6* 0.323
CBC  250 mL 89 43.8 51.6 124.9 115.1 81.1 112.3*
Pdet
CBC < 250 mL 85 26.6 15.8 23.6 14.6 3.07 13.1 0.872
CBC  250 mL 89 25.6 13.0 22.9 12.2 2.76 8.15*
CBC
CBC < 250 mL 85 157 49.8 258.8 106.9 101.7 99.3* 0.000
CBC  250 mL 89 349 81.7 370.3 134.5 21.8 143.9
# p value for the changes of data between groups; * p value< 0.05 between baseline
and 3 months within groups.
CBC¼ cystometric bladder capacity; FBC¼ functional bladder capacity; Pdet¼
detrusor pressure; PVR¼ postvoid residual; Qmax¼maximum ﬂow rate; UDS¼
urodynamic study.
Table 3
The changes of urodynamic variables at baseline and 3 months after intravesical
BoNT-A 100 U injection in patients with detrusor overactivity and different baseline
PVR.
UDS variables n Baseline 3 mo Changes p#
Qmax
PVR < 100 mL 144 13.1 6.13 12.7 6.59 -0.35 5.03 0.820
PVR  100 mL 30 10.2 5.3 10.1 5.49 -0.11 5.08
FBC
PVR < 100 mL 144 227.2 114.7 222.2 111.2 4.98 105.9 0.699
PVR  100 mL 30 179.6 101.8 166.2 89.4 -13.4 93.4
PVR
PVR < 100 mL 144 14.2 19.5 94.2 91.1 80.1 89.5* 0.191
PVR  100 mL 30 119.4 23.6 173.4 121.7 54.1 130.9*
Pdet
PVR < 100 mL 144 26.3 14.3 23.6 13.3 2.65 11.1* 0.534
PVR  100 mL 30 25.1 14.6 20.9 13.3 4.24 8.17*
CBC
PVR < 100 mL 144 239.7 113.8 311.6 131.4 71.9 121.2* 0.014
PVR  100 mL 30 339.1 100.8 343.9 144.7 4.79 158.1
# p value for the changes of data between groups; * p value< 0.05 between baseline
and 3 months within groups.
CBC¼ cystometric bladder capacity; FBC¼ functional bladder capacity; Pdet¼
detrusor pressure; PVR¼ postvoid residual; Qmax¼maximum ﬂow rate; UDS¼
urodynamic study.
Q.-S. Ke et al. / Tzu Chi Medical Journal 24 (2012) 121e126 123During the follow-up period, AUR occurred in 12 (6.9%) patients,
a large PVR 150 mL developed in 81 (46.6%) patients and 73 (42%)
patients needed to strain to void. Gross hematuria occurred in 17
(9.8%) patients, UTI developed in 27 (15.5%) patients and general
weakness was noted in 6 (3.4%) patients.
Tables 1e5 show the changes in CBC, Qmax, FBC, PVR, and Pdet
from baseline to 3 months after BoNT-A injection, in patient
subgroups with different baseline urodynamic variables. In patients
with a baseline CBC < 250 mL, the FBC and CBC at 3 months
increased signiﬁcantly compared with those with a baseline CBC 
250 mL. Patients with baseline Qmax < 10 mL/s had signiﬁcant
increases in the Qmax and FBC at 3 months, compared with those
with baseline Qmax  10 mL/s. Patients with a baseline PVR <
100 mL had a signiﬁcant increase of CBC at 3 months, comparedTable 2
The changes of urodynamic variables at baseline and 3 months after intravesical
BoNT-A 100 U injection in patients with detrusor overactivity and different baseline
Qmax.
UDS variables n Baseline 3 mo Changes p #
Qmax
Qmax < 10 mL/s 64 6.81 2.03 8.01 3.87 1.20 4.14* 0.006
Qmax  10 mL/s 110 15.6 5.24 14.5 6.46 1.11 5.28*
FBC
Qmax < 10 mL/s 64 146 82.7 166 93.6 19.6 98.7 0.023
Qmax  10 mL/s 110 256 110 236 110 20.1 104
PVR
Qmax < 10 mL/s 64 46.7 52.6 110 113 63.5 111* 0.293
Qmax  10 mL/s 110 25.6 39.0 106 92.8 80.0 87.0*
Pdet
Qmax < 10 mL/s 64 26.8 16.4 24.6 14.9 2.23 14.0 0.633
Qmax  10 mL/s 110 25.8 13.4 22.6 12.6 3.19 8.99*
CBC
Qmax < 10 mL/s 64 205 103 271 123 66.0 117 0.666
Qmax  10 mL/s 110 285 116 342 134 56.4 138*
# p value for the changes of data between groups; * p value< 0.05 between baseline
and 3 months within groups.
CBC¼ cystometric bladder capacity; FBC¼ functional bladder capacity; Pdet¼
detrusor pressure; PVR¼ postvoid residual; Qmax¼maximum ﬂow rate; UDS¼
urodynamic study.with those with a baseline PVR  100 mL. However, patients with
baseline VE < 70% or  70%, and those with phasic or terminal DO,
did not differ in any urodynamic change after BoNT-A injection.
Table 6 shows the success rates at 3 months and the occurrence
of AE between patient subgroups with different baseline urody-
namic parameters. The only signiﬁcant urodynamic factor was
a baseline PVR  100 mL, which resulted in a higher rate of AUR,
and more patients needing to strain to void.
Fig. 1 shows the cumulative success rates between subgroups
with different baseline urodynamic variables. There were no
signiﬁcant differences in the cumulative success rates between any
patient subgroup with: CBC  250 mL or CBC < 250 mL, Qmax 
10 mL/s or Qmax <10 mL/s, PVR  100 mL or PVR < 100 mL, VE 
70% or VE < 70%, and those with phasic or terminal DO.Table 4
The changes of urodynamic variables at baseline and 3 months after intravesical
BoNT-A 100 U injection in patients with detrusor overactivity and different baseline
voiding efﬁciency.
UDS variables n Baseline 3 mo Changes p#
Qmax
VE < 70% 27 8.27 4.43 9.20 4.87 0.93 4.81 0.214
VE  70% 147 13.3 6.03 12.8 6.58 0.52 5.05
FBC
VE < 70% 27 119.2 48.8 141.4 80.4 22.2 82.9 0.161
VE  70% 147 235 113 224 109.5 11.3 106.1
PVR
VE < 70% 27 115.4 35.0 172.6 125 57.2 134* 0.339
VE  70% 147 18.0 27.0 95.0 90.8 77.0 88.4*
Pdet
VE < 70% 27 25.9 16.1 22.5 14.7 3.33 9.08 0.869
VE  70% 147 26.1 14.2 23.3 13.2 2.85 10.9*
CBC
VE < 70% 27 290 110 328 142 38.5 162 0.413
VE  70% 147 252 118 316 133 63.2 125*
# p value for the changes of data between groups; * p value< 0.05 between baseline
and 3 months within groups.
CBC¼ cystometric bladder capacity; FBC¼ functional bladder capacity; Pdet¼
detrusor pressure; PVR¼ postvoid residual; Qmax¼maximum ﬂow rate; UDS¼
urodynamic study.
Table 5
The changes of urodynamic variables at baseline and 3 months after intravesical
BoNT-A 100 U injection in patients with different types of baseline detrusor
overactivity.
UDS variables n Baseline 3 mo Changes p#
Qmax
Phasic DO 100 12.9 6.22 12.2 6.46 -0.65 4.62 0.325
Terminal DO 74 12.2 5.90 12.3 6.53 0.16 5.52
FBC
Phasic DO 100 214 117 210 106 -3.64 108 0.691
Terminal DO 74 225 109 214 115 -10.4 98.6
PVR
Phasic DO 100 32.7 49.6 104 106 71.7 101* 0.568
Terminal DO 74 34.2 39.1 115 96.0 80.6 94.5*
Pdet
Phasic DO 100 24.0 12.4 21.4 12.4 -2.68 9.99* 0.787
Terminal DO 74 28.8 16.2 25.6 14.2 -3.19 11.6*
CBC
Phasic DO 100 254 125 308 126 54.2 141* 0.549
Terminal DO 74 263 107 330 144 67.0 117*
# p value for the changes of data between groups; * p value< 0.05 between baseline
and 3 months within groups.
CBC¼ cystometric bladder capacity; DO¼ detrusor overactivity; FBC¼ functional
bladder capacity; Pdet¼ detrusor pressure; PVR¼ postvoid residual; Qmax¼
maximum ﬂow rate; UDS¼ urodynamic study.
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This study found that baseline urodynamic parameters do not
generally affect the long term therapeutic outcome and occurrence
of AEs after 100 U BoNT-A injection in patients with IDO. However,
patients with phasic DO had a higher success rate than those with
terminal DO at 3 months. Although a baseline PVR  100 mL may
yield a higher rate of AUR and straining to void, the long-term
success rate was not inferior to that in patients with a PVR
< 100 mL.
In the past decade, intravesical BoNT-A injection has been
shown to be an effective therapeutic alternative for IDO refractory
to antimuscarinics. Urinary frequency and episodes of incontinence
improve after BoNT-A injection [20]. Although clinical trials have
provided evidence for the efﬁcacy of BoNT-A in patients with OAB,
the incidence of AEs remains high, and also seems to have been
underreported. Increased doses of BoNT-A do not add additional
beneﬁts, but do increase the incidence of AEs, especially a large PVR
and AUR needing CIC [9].
Although numerous studies have explored the underlying
pathophysiology of DO, the actual mechanism of developmentTable 6
Correlation of success rate and the incidence of adverse events with baseline urodynam
n Success rate AUR Large PVR
CBC < 250 mL 85 65 (77.4%) 5 (6.0%) 35 (41.7%)
CBC  250 mL 89 72 (80.9%) 7 (7.9%) 45 (50.6%)
p 0.351 0.424 0.154
Qmax < 10 mL/s 64 52 (82.5%) 6 (9.5%) 31 (49.2%)
Qmax  10 mL/s 110 85 (77.3%) 6 (5.5%) 49 (44.5%)
p 0.268 0.238 0.332
PVR <100 mL 144 113 (79%) 6 (4.2%) 63 (43.8%)
PVR 100 mL 30 25 (83.3%) 6 (20%) 18 (60%)
p 0.374 0.007 0.078
VE < 70% 27 22 (81.5%) 3 (11%) 16 (59.3%)
VE  70% 147 115 (79%) 9 (6.2%) 64 (43.8%)
p 0.490 0.282 0.103
Phasic DO 100 84 (84%) 5 (5%) 48 (48%)
Terminal DO 74 54 (73%) 7 (9.5%) 33 (46%)
p 0.050 0.198 0.386
AUR¼ acute urinary retention; CBC¼ cystometric bladder capacity; DO¼ detrusor overa
rate; UTI¼ urinary tract infection; VE¼ voiding efﬁciency.of DO is not fully understood. Urothelial dysfunction, myogenic
hyperactivity, neuromuscular junction dysfunction and a central
nervous system (CNS) inhibitory deﬁcit, might contribute to the
occurrence of DO [21e24]. There is also no useful biomarker to
identify the pathophysiology of DO [25]. Most urologists
diagnose and treat DO based on urodynamic study and assess the
treatment outcome by increases in bladder capacity or symptom-
atic improvement. Clinical parameters, such as bladder capacity,
voided volume and PVR, in part, might reﬂect the underlying
pathophysiology of DO [26].
DO might occur during the storage phase or at bladder capacity,
which results in phasic or terminal detrusor contractions, respec-
tively. Parasympathetic activity during the bladder storage phase is
supposed to be silent, therefore, any detrusor contractions occur-
ring during the storage phase are likely to be mediated by sensory
afferent ﬁbers other than parasympathetic cholinergic ﬁbers
[13,14]. Two signaling pathways can be identiﬁed in bladder
afferent mechanisms. The urothelial pathway is a functional unit
consisting of the urothelium, interstitial cells and afferent nerves in
the lamina propria. Signaling occurs via muscle-mucosal mecha-
noreceptors, mucosal mechanoreceptors and chemoreceptors. The
myogenic pathway is activated via in-series mechanoreceptors
responding to distention, and via spontaneous contractile activity
in units of myocytes generating afferent noise [27]. Phasic DO
during the storage phase might be mainly due to increased sensory
input from urothelial dysfunction, and therefore, the bladder also
shows oversensitivity and a small capacity [28]. Terminal DOmight
involve increased muscarinic receptor expression or lack of an
inhibitory effect from the CNS [24]. These different types of DO
might have different responses to intravesical BoNT-A injection.
The results of this study revealed that the success rate at 3 months
was lower in patients with terminal DO, suggesting that the lack of
CNS inhibition might play an important role in the failed treatment
in these patients.
In this study, patients with a small baseline CBC (< 250 mL) had
a signiﬁcantly greater increment of FBC and CBC after BoNT-A
injection than those with a CBC  250 mL at baseline. The PVR
changes between these 2 groups were not different, therefore, the
differences in CBC and FBC changes between groups are likely to
result from a true bladder capacity increase after BoNT-A injection.
Although the actual mechanism has not been elucidated, we
speculate that the pathophysiology might be different between DO
patients with a small and large CBC.
In clinical practice, DO is often associated with bladder over-
sensitivity [28]. Urothelial dysfunction has been considered to be
responsible for DO in patients with a small CBC [29]. On the otheric variables.
Straining to void Hematuria UTI General weakness
30 (35.7%) 9 (10.7%) 15 (18%) 3 (3.65%)
42 (47.2%) 8 (9.0%) 12 (14%) 3 (3.4%)
0.084 0.449 0.280 0.631
24 (38.1%) 4 (6.3%) 6 (9.5%) 3 (4.8%)
48 (43.6%) 13 (11.8%) 21 (19%) 3 (2.7%)
0.291 0.186 0.071 0.381
55 (38.2%) 15 (10.4%) 22 (15%) 3 (2.1%)
18 (60%) 2 (6.7%) 5 (17%) 3 (10%)
0.023 0.409 0.517 0.065
14 (51.9%) 1 (3.7%) 5 (18.5%) 3 (11%)
58 (39.7%) 16 (11%) 22 (15%) 3 (2.1%)
0.168 0.217 0.417 0.049
41 (41%) 6 (6%) 19 (19%) 3 (3%)
32 (43.2%) 11 (14.9%) 8 (10.8%) 3 (4.1)
0.443 0.046 0.102 0.509
ctivity; Pdet¼ detrusor pressure; PVR¼ postvoid residual; Qmax¼maximum ﬂow
Fig. 1. Kaplan-Meier survival curves for the cumulative success rates of different patient subgroups with varying baseline urodynamic parameters. The treatment outcome was
assessed using the patient perception of bladder condition (PPBC), with an improvement of the PPBC score from baseline of  2 considered to be a successful outcome. There was no
signiﬁcant difference in the success rate in all comparisons.
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inhibitory deﬁciency from CNS control. Therefore, the effects on
CBC and FBC after BoNT-A injection are different. Our previous
study also showed that improvement of urgency severity is
signiﬁcantly associated with a higher success rate at 3 months and
longer therapeutic duration after intravesical BoNT-A injection for
IDO, suggesting that effective urothelial sensory nerve desensiti-
zation is important in the mechanism of action of BoNT-A on
DO [30].
Another interesting ﬁnding is that patients with a baseline
PVR < 100 mL had a signiﬁcantly greater increment in CBC after
BoNT-A injection than with those with a baseline PVR >100 mL. A
higher baseline PVR may result in a greater risk of AUR and theneed to strain to void. Although the CBC increased, the PVR also
increased signiﬁcantly after BoNT-A injection, resulting in a smaller
FBC in patients with a baseline PVR > 100 mL. A large PVR reﬂects
lower detrusor contractility, which might be a consequence of
aging, bladder ischemia, myogenic effect or partial denervation
[31]. Whether these factors inﬂuence the action of BoNT-A
deserves further investigation, and might provide pharmacolog-
ical perspectives in the treatment of DO [32].
In conclusion, except for patients with phasic DO, the baseline
urodynamic parameters did not affect the treatment outcome after
intravesical injection of 100 U BoNT-A for IDO. AUR and difﬁcult
urination occurred signiﬁcantly more often in patients with
a baseline PVR  100 mL. However, the occurrence of a large PVR
Q.-S. Ke et al. / Tzu Chi Medical Journal 24 (2012) 121e126126after treatment did not affect the success rate at 3 months or long-
term follow-up.References
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